In brief
- The journal Addiction has published a qualitative analysis of ten individuals with alcohol use disorder who received intranasal 5-MeO-DMT paired with cognitive behavioral therapy.
- Participants describe the session using metaphors of resetting, cleansing, or rebirth, followed by greater clarity regarding their relationship with alcohol.
- This was an open-label phase 2a trial with no placebo and only ten participants; two authors work for the company developing the formulation.
Ten people with moderate to severe alcohol use disorder received a single intranasal dose of 5-MeO-DMT alongside cognitive behavioral therapy designed for relapse prevention. Addiction, one of the leading journals in the field, has published a qualitative analysis of these sessions: how participants experienced them, what changed in the weeks that followed, and what their accompanying therapists observed.
The participants’ accounts
The research team, which includes scientists from King’s College London and British company Beckley Psytech, interviewed all ten participants the day after dosing and again twelve weeks later, as well as the six therapists involved. The word that surfaced most frequently right after the experience was “reset”: participants spoke of cleansing, starting fresh, moments of emotional catharsis, and a clearer perspective on why they drank. 5-MeO-DMT produces a very brief and intense effect, quite different in duration from ayahuasca, which is ingested orally with harmine and extends the experience across several hours.
The numbers, and their limits
At twelve weeks, five of the ten participants remained abstinent, describing the session as a turning point that helped them reexamine their identity and habits. Two others had resumed drinking, but in moderation and with greater awareness of their triggers. The therapists agreed that they observed increased psychological flexibility and emotional openness, even in those who had a challenging time during the session. Caveats are essential here: this was an open-label study, every participant knew what they were receiving, the sample size is tiny, and there was no control group. It is part of a phase 2a trial designed primarily to assess safety and feasibility. Furthermore, two of the authors are employed by the company developing this formulation—a factor worth keeping in mind when calibrating enthusiasm.
What it means
A qualitative study like this cannot answer whether the compound curbs alcohol consumption better than a placebo. It answers a different question: what the experience is actually like for people. That insight helps clinicians better tailor the psychological support surrounding dosing—a variable that research on DMT and related compounds repeatedly highlights as crucial. The honest takeaway is modest: in a very small cohort over three months of follow-up, a brief and intense experience appears to open a window for rethinking one’s relationship with alcohol when paired with structured therapy. Nothing more, nothing less. The insight that truly extends beyond the laboratory is clear: the framework surrounding the substance matters just as much as the substance itself.
Source
- Seynaeve, M., Dunbar, F., Ermakova, A. O. et al. Psychological change processes in alcohol use disorder: a qualitative study of 5-MeO-DMT with cognitive behavioural therapy. Addiction, August 3, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
